Craiova

• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 5 2023-06-21 axial spondyloarthritis
• A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm … Recruiting
  2023-504595-26-00 4 2023-05-22 Non-Small Cell Lung Cancer
• Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery Recruiting
  2024-515830-34-00 5 2023-02-14 Congenital antithrombin deficiency
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Recruiting
  2025-522204-24-00 4 2026-06-16 Drug-Related Side Effects and Adverse Reactions
• A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Recruiting
  2025-523544-12-00 5 2026-06-02 Myelodysplastic neoplasms/syndromes (MDS)
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes
• AMAZE 2: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and type 2 diabetes lose wei … Recruiting
  2024-520441-23-00 5 2026-05-13 Overweight or obesity, and type 2 diabetes
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08 Obesity
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 Small Cell Lung Cancer (SCLC)
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E … Recruiting
  2025-523552-31-00 5 2026-05-07 Systemic Lupus Erythematosus
• Testing HLX43 in Advanced Lung Cancer (Non-Small Cell): A Global Safety and Effectiveness Study Recruiting
  2025-523803-31-00 4 2026-04-16 Advanced non-small cell lung cancer (NSCLC)
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 4 2026-04-13 Mild to moderate asthma
• Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Previously Untreated Advanced or Me … Recruiting
  2025-523263-37-00 10 2026-04-08 Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
• Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met … Recruiting
  2025-523224-45-00 10 2026-03-30 Untreated, Unresectable or Metastatic Colorectal Cancer
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 5 2026-03-24 Metastatic castration resistant prostate cancer
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI) Recruiting
  2025-522514-23-00 5 2026-02-12 Urinary Incontinence
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 English First-line extensive-stage small-cell lung cancer (ES-SCLC)
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af … Recruiting
  2025-522400-24-00 10 2026-01-27 Metastatic urothelial cancer
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Advanced Clear Cell Renal Cell Carcinoma

Showing 49–72 of 307 trials